LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection

Journal of Clinical Microbiology

Volumn 49, Issue 1, 2011, Pages 111-117

  Gu, Jingmin ^a   Xu, Wei ^b   Lei, Liancheng ^a   Huang, Jing ^b   Feng, Xin ^a   Sun, Changjiang ^a   Du, Chongtao ^a   Zuo, Jing ^a   Li, Yang ^a   Du, Taofeng ^a   Li, Nxi ^a   Han, Wenyu ^a  

^a JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIOPHAGE LYSIN LYSGH15; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM ISOLATION; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SINGLE DRUG DOSE;

ANIMALS; BACTEREMIA; DISEASE MODELS, ANIMAL; DNA, VIRAL; FEMALE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; MOLECULAR SEQUENCE DATA; MUCOPROTEINS; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS PHAGES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL PROTEINS;

ANIMALIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MURINAE; MUS; STAPHYLOCOCCUS AUREUS;

EID: 78650865739     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01144-10     Document Type: Article

References (38)

1. Borysowski, J., B. Weber-Dabrowska, and A. Gorski. 2006. Bacteriophage endolysins as a novel class of antibacterial agents. Exp. Biol. Med. (Maywood) 231:366-377.
2. Brumfitt, W., and J. Hamilton-Miller. 1989. Methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 320:1188-1196.
3. Casal, J., L. Aguilar, I. Jado, J. Yuste, M. J. Gimenez, J. Prieto, and A. Fenoll. 2002. Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model. Antimicrob. Agents Chemother. 46:1340-1344.
4. Chang, H. C., C. R. Chen, J. W. Lin, G. H. Shen, K. M. Chang, Y. H. Tseng, and S. F. Weng. 2005. Isolation and characterization of novel giant Stenotrophomonas maltophilia phage phiSMA5. Appl. Environ. Microbiol. 71:1387-1393.
5. Cheng, Q., and V. A. Fischetti. 2007. Mutagenesis of a bacteriophage lytic enzyme PlyGBS significantly increases its antibacterial activity against group B streptococci. Appl. Microbiol. Biotechnol. 74:1284-1291.
6. Daniel, A., C. Euler, M. Collin, P. Chahales, K. J. Gorelick, and V. A. Fischetti. 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:1603-1612.
7. Donovan, D. M. 2007. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications. Recent Pat. Biotechnol. 1:113-122.
8. Ellis, E. L., and M. Delbruck. 1939. The growth of bacteriophage. J. Gen. Physiol. 22:365-384.
9. Enright, M. C. 2003. The evolution of a resistant pathogen - the case of MRSA. Curr. Opin. Pharmacol. 3:474-479.
10. Fischetti, V. A. 2005. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol. 13:491-496.
11. Fischetti, V. A. 2003. Novel method to control pathogenic bacteria on human mucous membranes. Ann. N. Y. Acad. Sci. 987:207-214.
12. Fischetti, V. A. 2006. Using phage lytic enzymes to control pathogenic bacteria. BMC Oral Health 6(Suppl. 1):S16.
13. García, E., J. L. Garcia, P. Garcia, A. Arraras, J. M. Sanchez-Puelles, and R. Lopez. 1988. Molecular evolution of lytic enzymes of Streptococcus pneumoniae and its bacteriophages. Proc. Natl. Acad. Sci. U. S. A. 85:914-918.
14. García, J. L., E. Garcia, A. Arraras, P. Garcia, C. Ronda, and R. Lopez. 1987. Cloning, purification, and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin. J. Virol. 61:2573-2580.
15. Hashimoto, H. 1994. Drug resistance of methicillin-resistant Staphylococcus aureus (MRSA) in Japan until 1993. Jpn. J. Antibiot. 47:575-584. (Pubitemid 24240146)
16. Haugen, P., D. M. Simon, and D. Bhattacharya. 2005. The natural history of group I introns. Trends Genet. 21:111-119.
17. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
18. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
19. Horgan, M., G. O'Flynn, J. Garry, J. Cooney, A. Coffey, G. F. Fitzgerald, R. P. Ross, and O. McAuliffe. 2009. Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. Appl. Environ. Microbiol. 75:872-874.
20. Jado, I., R. Lopez, E. Garcia, A. Fenoll, J. Casal, and P. Garcia. 2003. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 52:967-973.
21. Loeffler, J. M., D. Nelson, and V. A. Fischetti. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172.
22. Loessner, M. J. 2005. Bacteriophage endolysins - current state of research and applications. Curr. Opin. Microbiol. 8:480-487.
23. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
24. Matsuzaki, S., M. Yasuda, H. Nishikawa, M. Kuroda, T. Ujihara, T. Shuin, Y. Shen, Z. Jin, S. Fujimoto, M. D. Nasimuzzaman, H. Wakiguchi, S. Sugihara, T. Sugiura, S. Koda, A. Muraoka, and S. Imai. 2003. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J. Infect. Dis. 187:613-624.
25. Miller, L. G., F. Perdreau-Remington, G. Rieg, S. Mehdi, J. Perlroth, A. S. Bayer, A. W. Tang, T. O. Phung, and B. Spellberg. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1445-1453.
26. Mylotte, J. M., C. McDermott, and J. A. Spooner. 1987. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev. Infect. Dis. 9:891-907.
27. Nasu, H., T. Iida, T. Sugahara, Y. Yamaichi, K. S. Park, K. Yokoyama, K. Makino, H. Shinagawa, and T. Honda. 2000. A filamentous phage associated with recent pandemic Vibrio parahaemolyticus O3:K6 strains. J. Clin. Microbiol. 38:2156-2161.
28. Navarre, W. W., H. Ton-That, K. F. Faull, and O. Schneewind. 1999. Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi11. Identification of a D-alanyl-glycine endopeptidase activity. J. Biol. Chem. 274:15847-15856.
29. Nelson, D., L. Loomis, and V. A. Fischetti. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. U. S. A. 98:4107-4112.
30. Obeso, J. M., B. Martinez, A. Rodriguez, and P. Garcia. 2008. Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against Staphylococcus aureus in milk. Int. J. Food Microbiol. 128:212-218.
31. O'Flaherty, S., A. Coffey, R. Edwards, W. Meaney, G. F. Fitzgerald, and R. P. Ross. 2004. Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low G C content. J. Bacteriol. 186:2862-2871.
32. O'Flaherty, S., A. Coffey, W. Meaney, G. F. Fitzgerald, and R. P. Ross. 2005. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J. Bacteriol. 187:7161-7164.
33. Rashel, M., J. Uchiyama, T. Ujihara, Y. Uehara, S. Kuramoto, S. Sugihara, K. Yagyu, A. Muraoka, M. Sugai, K. Hiramatsu, K. Honke, and S. Matsuzaki. 2007. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J. Infect. Dis. 196:1237-1247.
34. Sass, P., and G. Bierbaum. 2007. Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl. Environ. Microbiol. 73:347-352.
35. Schuch, R., D. Nelson, and V. A. Fischetti. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-889.
36. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.
37. Weigel, L. M., D. B. Clewell, S. R. Gill, N. C. Clark, L. K. McDougal, S. E. Flannagan, J. F. Kolonay, J. Shetty, G. E. Killgore, and F. C. Tenover. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302:1569-1571.
38. Zhao, W. H., Z. Q. Hu, S. Okubo, Y. Hara, and T. Shimamura. 2001. Mechanism of synergy between epigallocatechin gallate and beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:1737-1742.